Clin Psychopharmacol Neurosci.
2020 Feb;18(1):159-163. 10.9758/cpn.2020.18.1.159.
Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
- Affiliations
-
- 1Departments of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
- 2Departments of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Japan
- 3Office of Clinical Pharmacy Practice and Health Care Management, Faculty of Pharmacy, Meijo University, Nagoya, Japan
- KMID: 2502138
- DOI: http://doi.org/10.9758/cpn.2020.18.1.159
Abstract
- In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release
- Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia
- Antipsychotics Prescribing Patterns of Patients with Schizophrenia Admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008
- Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy
- Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
